Stellant Securities allots shares and warrants at ₹602

Stellant Securities (India) Ltd allotted 678,388 equity shares at ₹602 each for cash consideration of ₹408.39 million and 166,200 convertible warrants at the same price on November 4, 2026. The preferential allotment follows shareholder approval in August and BSE in-principle approval in October, while increasing the company’s equity base.

What did Stellant Securities approve on November 4, 2026?

Stellant Securities approved the allotment of 678,388 equity shares and 166,200 convertible warrants, with each security priced at ₹602. The equity-share allotment was made to non-promoter public investors, while the warrant allotment was made to the promoter group, according to the company’s filing.

The equity shares have a face value of ₹10 each and include a premium of ₹592 per share. The 678,388 shares carry total cash consideration of ₹408.39 million. The 166,200 warrants are also priced at ₹602 each, representing an aggregate stated allotment value of ₹100.05 million.

A convertible warrant gives its holder the right to receive equity shares on conversion, subject to the terms of the preferential issue. The filing states that each warrant is convertible into one equity share of face value ₹10. The present allotment therefore has an immediate equity component and a potential future equity component if the allotted warrants are converted.

How does the allotment relate to BSE's approval?

The November 4 allotment is smaller than the issue for which BSE granted in-principle approval on October 21, 2026. BSE’s approval covered up to 1,289,177 equity shares for non-promoters and up to 348,837 convertible warrants for the promoter category, at a price of not less than ₹602 per security.

The exchange approval was communicated by Stellant Securities on October 22 under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The approval enabled the company to proceed with the proposed preferential issue, but it did not by itself constitute final listing approval for the securities.

Shareholders had approved the preferential issue on August 24, 2026. The sequence of shareholder approval, exchange in-principle approval and board allotment forms the regulatory path disclosed by the company for the current issuance.

Why does the preferential issue dilute existing shareholders?

The allotment dilutes existing shareholders because Stellant Securities has issued new equity shares rather than transferring shares held by existing investors. The 678,388 new shares expand the outstanding equity share capital, reducing the percentage ownership of shareholders who do not participate in the issue.

The warrants add a further potential source of dilution. If all 166,200 allotted warrants are converted, an equal number of additional equity shares would be issued. The actual change in ownership percentages cannot be calculated from the available disclosure because it does not provide the company’s pre-allotment outstanding share capital or the final post-issue shareholding pattern.

The distinction between the two components is important. Shares are allotted immediately and carry immediate dilution, whereas warrants convert into equity shares only when conversion takes place under the issue terms. Investors will need to track subsequent exchange approvals and company disclosures concerning listing and conversion of any new shares arising from the warrants.

What is the background to Stellant Securities' 2026 capital actions?

The November allotment follows other disclosed capital-market actions by Stellant Securities during 2026. On February 2, the company reported an allotment of 1,833,595 equity shares to the non-promoter group and 300,000 warrants to promoters and the promoter group for cash consideration.

The company also received approvals connected with the conversion of earlier preferential warrants. BSE granted in-principle listing approval in September 2026 for 150,000 equity shares allotted after warrant conversion, followed by trading approval for those 150,000 shares on September 16, 2026.

These filings show that preferential allotments and warrant conversions have been a recurring route for the company’s equity-capital actions in 2026. However, the available announcements do not state the intended use of the ₹408.39 million raised through the current equity-share allotment. No conclusion on the use of proceeds can therefore be drawn from the disclosed material.

What should investors monitor after the allotment?

Investors should monitor the listing process for the newly allotted equity shares and any shares issued on warrant conversion. BSE’s October approval specifically noted that final listing of the securities remains subject to separate compliance with applicable requirements.

The key figures to follow are the balance of the approved issue that has not yet been allotted and the conversion of the 166,200 current warrants. Based on the disclosed figures, 610,789 equity shares and 182,637 warrants remain unallotted relative to the October in-principle approval, assuming no other allotments under that approval have occurred.

The issue price of ₹602 provides a common benchmark across both the share and warrant portions of the present transaction. But the disclosed information does not provide a market-price reaction, post-issue promoter holding, or a timetable for further allotments. Investors should rely on subsequent exchange filings for those details.

Conclusion

Stellant Securities has completed a preferential allotment of 678,388 equity shares for ₹408.39 million and 166,200 convertible warrants, both priced at ₹602 per unit. The transaction follows shareholder and BSE approvals, adds new equity immediately, and creates potential additional dilution if the warrants are converted.

The next disclosures to watch are final listing approvals for the allotted shares, any further allotment from the BSE-approved issue, and conversion updates for the warrants. The company’s filings do not specify the use of the current equity proceeds or a schedule for completing the balance of the approved issuance.